시간 외 거래: 230.57

Biogen Inc (BIIB)

Biogen Inc 주식(BIIB)의 최신 뉴스

Biogen Inc (BIIB)

Biogen Inc 주식(BIIB)의 최신 뉴스

Ionis, Biogen Down on Ending Development of ALS Drug - Markets Insider

Ionis (IONS), Biogen Down on Ending Development of ALS Drug - Zacks Investment Research

Ionis (IONS), Biogen Down on Ending Development of ALS Drug - Yahoo Finance

Should You Worry About Biogen Inc.'s (NASDAQ:BIIB) CEO Salary Level? - Yahoo New Zealand News

Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone - Scrip

Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Clinical Trials Arena

Subcutaneous Maintenance Dosing for Early Alzheimer's Disease Now Under FDA Fast Track Status - Precision Vaccinations

Biogen, Ionis to discontinue development of experimental ALS drug - Reuters

Biogen and Ionis Pharma shares slide as they end development of ALS treatment - MarketWatch

Biogen also drops collaboration with Ionis on Angelman syndrome candidate - Seeking Alpha

Biogen CEO Looks for Small Deals While Alzheimer's Drug Ramps Up - Bloomberg

Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Clinical Trials Arena

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To - Benzinga

Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop - Pharmaceutical Technology

Biogen and Ionis halt ALS drug development after trial setback - Investing.com

Biogen, Ionis to discontinue development of experimental ALS drug - Reuters

Biogen walks away from Ionis-partnered ALS, Angelman prospects after peek at clinical data - Fierce Biotech

Biogen falls after discontinuing development of ALS drug - XM

Biogen stock Ionis stock drop on ALS setback (NASDAQ:BIIB) - Seeking Alpha

ALS treatment from Biogen, Ionis fails in study - STAT

ALS treatment from Biogen, Ionis fails in study - STAT

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news - STAT

Biogen, Ionis Terminate Development of BIIB105 for Amyotrophic Lateral Sclerosis - MarketWatch

Biogen Shares Update on Angelman Syndrome Program - XM

Biogen, Ionis will discontinue development of their ALS drug - WTVB

Biogen, Ionis will discontinue development of their ALS drug - WKZO

Biogen, Ionis will discontinue development of their ALS drug - WTAQ

Statement: Biogen Shares Update on Angelman Syndrome Program | Biogen - Biogen

Biogen, Ionis to discontinue development of ALS drug - XM

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - GlobeNewswire

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis - PR Newswire

Biogen Inc. (NASDAQ:BIIB) Stake Boosted by Private Advisor Group LLC - Defense World

Biogen, Ionis to discontinue development of experimental ALS drug - Reuters.com

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Biogen Stock Continues Its 24% Sprint On An Alzheimer's Treatment Twist - Investor's Business Daily

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector - Yahoo Finance

Eisai starts rolling submission for injectable version of Alzheimer's drug with US FDA - Reuters.com

Eisai predicts sharp Leqembi sales increase as launch efforts begin to bear fruit - FiercePharma

Eisai begins FDA submissions for injectable Alzheimer's drug - Seeking Alpha

Eisai, Biogen Launch Rolling BLA for Subcutaneous Alzheimer’s Therapy Leqembi - BioSpace

Biogen and Eisai announce rolling FDA submission for injectable version of Alzheimer's drug - PMLiVE

Eisai begins rolling submission for SC Leqembi - The Pharma Letter

Eisai, Biogen start delayed subcutaneous Leqembi filing - pharmaphorum

Eisai And Biogen Fast-Track FDA Approval For A New Alzheimer's Treatment - Finimize

After filing hitch, Eisai and Biogen begin rolling FDA submission for subcutaneous Leqembi - FiercePharma

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous ... - PR Newswire

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know - Yahoo Singapore News

Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch

Biogen Inc. (NASDAQ:BIIB) Shares Sold by Lincoln National Corp - Defense World

BIIB과 유사한 종목